Pharmacokinetic/Pharmacodynamic Relationships of A

Clinical Pharmacokinetics

44, 367-393

DOI: 10.2165/00003088-200544040-00003

Citation Report

#	Article	IF	Citations
1	Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens usingEscherichia Coli-asparaginase orErwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL). Pediatric Blood and Cancer, 2006, 47, 299-304.	0.8	16
2	Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood, 2007, 109, 2744-2750.	0.6	145
3	Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood, 2007, 110, 1429-1438.	0.6	47
4	Clinical Pharmacology of Asparaginases in the United States: Asparaginase Population Pharmacokinetic and Pharmacodynamic (PK-PD) Models (NONMEM) in Adult and Pediatric ALL Patients. Journal of Pediatric Hematology/Oncology, 2007, 29, 239-247.	0.3	31
5	l-Asparaginase from Erwinia Chrysanthemi 3937: Cloning, expression and characterization. Journal of Biotechnology, 2007, 127, 657-669.	1.9	139
6	FDA Drug Approval Summary: Pegaspargase (OncasparÂ®) for the First-Line Treatment of Children with Acute Lymphoblastic Leukemia (ALL). Oncologist, 2007, 12, 991-998.	1.9	262
7	L-Asparaginase: A Promising Chemotherapeutic Agent. Critical Reviews in Biotechnology, 2007, 27, 45-62.	5.1	171
8	Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer, 2007, 110, 103-111.	2.0	599
9	Modification of recombinant asparaginase from Erwinia carotovora with polyethylene glycol 5000. Biochemistry (Moscow) Supplement Series B: Biomedical Chemistry, 2007, 1, 230-232.	0.2	5
10	Anti-cancer PEG-enzymes: 30Âyears old, but still a current approach. Advanced Drug Delivery Reviews, 2008, 60, 69-78.	6.6	131
11	Octreotide prevents l-asparaginaseâ€"induced pancreatic injury in rats. Experimental Hematology, 2008, 36, 172-180.	0.2	15
12	Population Pharmacokinetics and Pharmacodynamics for Treatment Optimization??in Clinical Oncology. Clinical Pharmacokinetics, 2008, 47, 487-513.	1.6	36
13	The Treatment of Adults with Acute Lymphoblastic Leukemia. Hematology American Society of Hematology Education Program, 2008, 2008, 381-389.	0.9	28
14	Pharmacokinetics, pharmacodynamics, efficacy, and safety of a new recombinant asparaginase preparation in children with previously untreated acute lymphoblastic leukemia: a randomized phase 2 clinical trial. Blood, 2008, 112, 4832-4838.	0.6	70
15	First-line treatment of acute lymphoblastic leukemia with pegasparaginase. Biologics: Targets and Therapy, 0, , 359.	3.0	11
16	A dyad of lymphoblastic lysosomal cysteine proteases degrades the antileukemic drug l-asparaginase. Journal of Clinical Investigation, 2009, 119, 1964-73.	3.9	69
17	Pegasparaginase: where do we stand?. Expert Opinion on Biological Therapy, 2009, 9, 111-119.	1.4	57
18	The ex vivo production of ammonia predicts l-asparaginase biological activity in children with acute lymphoblastic leukemia. International Journal of Hematology, 2009, 90, 347-352.	0.7	13

#	Article	IF	Citations
19	Structure ofHelicobacter pylori<scp>L</scp>-asparaginase at 1.4â€…Ã… resolution. Acta Crystallographica Section D: Biological Crystallography, 2009, 65, 1253-1261.	2.5	19
20	Optimal management of adults with ALL. British Journal of Haematology, 2009, 144, 468-483.	1.2	47
21	Comparison of Native E. coli and PEG Asparaginase Pharmacokinetics and Pharmacodynamics in Pediatric Acute Lymphoblastic Leukemia. Clinical Pharmacology and Therapeutics, 2009, 86, 651-658.	2.3	66
22	Tolerability and Efficacy of L-Asparaginase Therapy in Pediatric Patients With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2010, 32, 554-563.	0.3	97
23	Glutamine addiction: a new therapeutic target in cancer. Trends in Biochemical Sciences, 2010, 35, 427-433.	3.7	1,422
24	A population pharmacokinetic model for pegylatedâ€asparaginase in children. British Journal of Haematology, 2010, 148, 119-125.	1.2	32
26	Peg-asparaginase for acute lymphoblastic leukemia. Expert Opinion on Biological Therapy, 2010, 10, 833-839.	1.4	49
27	Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leukemia and Lymphoma, 2011, 52, 2237-2253.	0.6	198
28	Current Therapeutic Strategies in Adult Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America, 2011, 25, 1255-1279.	0.9	17
29	Asparaginase revisited. Leukemia and Lymphoma, 2011, 52, 168-178.	0.6	90
30	Metabolic alterations in cancer cells and therapeutic implications. Chinese Journal of Cancer, 2011, 30, 508-525.	4.9	82
31	Asparaginases. Journal of Pediatric Hematology/Oncology, 2011, 33, 573-579.	0.3	18
32	Proteins from Erwinia asparaginase Erwinase^{Â®} and E. coli asparaginase 2 MEDAC^{Â®} for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear. Electrophoresis, 2011, 32, 1824-1828.	1.3	9
33	Bacterial Asparaginase: A Potential Antineoplastic Agent for Treatment of Acute Lymphoblastic Leukemia. , 2012, , 225-244.		1
34	Engineering Reduced-Immunogenicity Enzymes for Amino Acid Depletion Therapy in Cancer. Methods in Enzymology, 2012, 502, 291-319.	0.4	43
35	Role of L-asparaginase in acute lymphoblastic leukemia: focus on adult patients. Blood and Lymphatic Cancer: Targets and Therapy, 2012, , 117.	1.2	16
36	Asparaginaseâ€associated pancreatitis in children. British Journal of Haematology, 2012, 159, 18-27.	1.2	101
37	Glutamine Deprivation Enhances Antitumor Activity of 3-Bromopyruvate through the Stabilization of Monocarboxylate Transporter-1. Cancer Research, 2012, 72, 4526-4536.	0.4	44

#	Article	IF	Citations
38	De Novo Engineering of a Human Cystathionine-Î³-Lyase for Systemic <scp>l</scp>-Methionine Depletion Cancer Therapy. ACS Chemical Biology, 2012, 7, 1822-1829.	1.6	32
39	Erwinia asparaginase in pediatric acute lymphoblastic leukemia. Expert Opinion on Biological Therapy, 2012, 12, 1407-1414.	1.4	24
40	Cancer metabolism: current perspectives and future directions. Cell Death and Disease, 2012, 3, e248-e248.	2.7	327
41	L-Asparaginase-Induced Pancreatic Injury is Associated with an Imbalance in Plasma Amino Acid Levels. Drugs in R and D, 2012, 12, 49-55.	1.1	13
42	Asparagine and aspartic acid concentrations in bone marrow versus peripheral blood during Berlinâ€"Frankfurtâ€"MÃ¼nster-based induction therapy for childhood acute lymphoblastic leukemia. Leukemia and Lymphoma, 2012, 53, 1682-1687.	0.6	12
43	Chemotherapy-Induced Hepatotoxicity. Clinics in Liver Disease, 2013, 17, 671-686.	1.0	39
44	Therapeutic strategies impacting cancer cell glutamine metabolism. Future Medicinal Chemistry, 2013, 5, 1685-1700.	1.1	110
45	Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: a report from the Childrenâ€™s Oncology Group. Blood, 2013, 122, 507-514.	0.6	63
46	Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells. , 2013, , 677-690.		1
47	Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Studyâ€"Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Journal of Clinical Oncology, 2013, 31, 1202-1210.	0.8	274
48	Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia. Protein and Peptide Letters, 2013, 20, 392-402.	0.4	26
49	Managing Hypersensitivity to Asparaginase in Pediatrics, Adolescents, and Young Adults. Journal of Pediatric Oncology Nursing, 2013, 30, 63-77.	1.5	24
50	L-Carnitine Ameliorates L-Asparaginase-Induced Acute Liver Toxicity in Steatotic Rat Livers. Chemotherapy, 2013, 59, 167-175.	0.8	25
51	Recombinant expression, purification of L-asparaginase-II from thermotolerant E. Coli strain and evaluation of its antiproliferative activity. African Journal of Microbiology Research, 2014, 8, 1610-1619.	0.4	7
52	Identification and Structural Analysis of an l-Asparaginase Enzyme from Guinea Pig with Putative Tumor Cell Killing Properties. Journal of Biological Chemistry, 2014, 289, 33175-33186.	1.6	48
53	Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia. British Journal of Haematology, 2014, 166, 213-220.	1.2	27
54	Asparaginase in Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S14-S17.	0.2	39
55	Pharmacology, immunogenicity, and efficacy of a novel pegylated recombinant Erwinia chrysanthemi-derived L-asparaginase. Investigational New Drugs, 2014, 32, 795-805.	1.2	28

#	Article	IF	Citations
56	Cell-penetrating peptides meditated encapsulation of protein therapeutics into intact red blood cells and its application. Journal of Controlled Release, 2014, 176, 123-132.	4.8	108
57	Pharmacokinetic and Pharmacodynamic Properties of Calaspargase Pegol Escherichia coli L-Asparaginase in the Treatment of Patients With Acute Lymphoblastic Leukemia: Results From Children's Oncology Group Study AALL07P4. Journal of Clinical Oncology, 2014, 32, 3874-3882.	0.8	91
58	Crystal structure of active site mutant of antileukemic <scp>l</scp>â€asparaginase reveals conserved zincâ€binding site. FEBS Journal, 2014, 281, 4097-4111.	2.2	27
59	Structural and Kinetic Characterization of Guinea Pig <scp>l</scp>-Asparaginase Type III. Biochemistry, 2014, 53, 2318-2328.	1.2	29
60	Asparaginase in the treatment of non-ALL hematologic malignancies. Cancer Chemotherapy and Pharmacology, 2014, 73, 875-883.	1.1	31
61	Successful challenges using native E. coli asparaginase after hypersensitivity reactions to PEGylated E. coli asparaginase. Cancer Chemotherapy and Pharmacology, 2014, 73, 1307-1313.	1.1	20
62	Asparagine Depletion Potentiates the Cytotoxic Effect of Chemotherapy against Brain Tumors. Molecular Cancer Research, 2014, 12, 694-702.	1.5	61
63	How to manage asparaginase hypersensitivity in acute lymphoblastic leukemia. Future Oncology, 2014, 10, 2615-2627.	1.1	46
64	A germ line mutation in cathepsin B points toward a role in asparaginase pharmacokinetics. Blood, 2014, 124, 3027-3029.	0.6	12
65	Clinical application of asparaginase activity levels following treatment with pegaspargase. Pediatric Blood and Cancer, 2015, 62, 1102-1105.	0.8	35
66	Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Seminars in Hematology, 2015, 52, 165-171.	1.8	44
67	Depletion of T Cell Epitopes in Lysostaphin Mitigates Anti-Drug Antibody Response and Enhances Antibacterial Efficacy InÂVivo. Chemistry and Biology, 2015, 22, 629-639.	6.2	48
68	Best Practices in Adolescent and Young Adult Patients with Acute Lymphoblastic Leukemia: A Focus on Asparaginase. Journal of Adolescent and Young Adult Oncology, 2015, 4, 118-128.	0.7	48
69	Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment. Clinical Cancer Research, 2015, 21, 680-686.	3.2	83
70	Asparagine Synthetase Polymorphisms and Toxicity and Efficacy of Asparaginases. Clinical Cancer Research, 2015, 21, 230-232.	3.2	2
71	Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leukemia and Lymphoma, 2015, 56, 2273-2280.	0.6	125
72	Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy. Blood Reviews, 2015, 29, 243-249.	2.8	42
73	Glutaminase activity determines cytotoxicity of l-asparaginases on most leukemia cell lines. Leukemia Research, 2015, 39, 757-762.	0.4	81

#	Article	IF	Citations
74	Identification of Functional Regions in the Rhodospirillum rubrum l-Asparaginase by Site-Directed Mutagenesis. Molecular Biotechnology, 2015, 57, 251-264.	1.3	39
75	Cloning, expression and characterization of l-asparaginase from Pseudomonas fluorescens for large scale production in E. coli BL21. 3 Biotech, 2015, 5, 975-981.	1.1	31
76	Catalytic Role of the Substrate Defines Specificity of Therapeutic l-Asparaginase. Journal of Molecular Biology, 2015, 427, 2867-2885.	2.0	25
77	The Incidence of Hypersensitivity Reactions to Pegylated Asparaginase in Children With Acute Lymphoblastic Leukemia. Journal of Pediatric Hematology/Oncology, 2016, 38, e16-e20.	0.3	11
78	Immunology of infusion reactions in the treatment of patients with acute lymphoblastic leukemia. Future Oncology, 2016, 12, 1609-1621.	1.1	24
79	Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation. Journal of Controlled Release, 2016, 244, 184-193.	4.8	465
80	Use of PEG-asparaginase in newly diagnosed adults with standard-risk acute lymphoblastic leukemia compared with E. coli-asparaginase: a retrospective single-center study. Scientific Reports, 2016, 6, 39463.	1.6	7
81	Erythrocyte encapsulated <scp>l</scp>-asparaginase (GRASPA) in acute leukemia. International Journal of Hematologic Oncology, 2016, 5, 11-25.	0.7	20
82	Glutaminolysis and carcinogenesis of oral squamous cell carcinoma. European Archives of Oto-Rhino-Laryngology, 2016, 273, 495-503.	0.8	23
83	Recent developments in l-asparaginase discovery and its potential as anticancer agent. Critical Reviews in Oncology/Hematology, 2016, 100, 1-10.	2.0	155
84	Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase. Expert Review of Hematology, 2016, 9, 227-234.	1.0	14
85	Successful use of palifermin following severe anaphylaxis to pegaspargase in a pediatric patient with acute lymphoblastic leukemia. Journal of Oncology Pharmacy Practice, 2016, 22, 354-356.	0.5	2
86	Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. Journal of Neuro-Oncology, 2016, 128, 57-66.	1.4	26
87	Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 748-757.	0.6	175
88	Therapeutic<scp>l</scp>-asparaginase: upstream, downstream and beyond. Critical Reviews in Biotechnology, 2017, 37, 82-99.	5.1	109
89	Do immunoglobulin G and immunoglobulin E anti- l -asparaginase antibodies have distinct implications in children with acute lymphoblastic leukemia? A cross-sectional study. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 202-209.	0.7	9
90	In search of druggable targets for GBM amino acid metabolism. BMC Cancer, 2017, 17, 162.	1.1	67
91	Plasma asparaginase activity, asparagine concentration, and toxicity after administration of Erwinia asparaginase in children and young adults with acute lymphoblastic leukemia: Phase I/II clinical trial in Japan. Pediatric Blood and Cancer, 2017, 64, e26475.	0.8	3

#	Article	IF	Citations
92	Reactions related to asparaginase infusion in a 10-year retrospective cohort. Revista Brasileira De Hematologia E Hemoterapia, 2017, 39, 337-342.	0.7	16
93	A protease-resistant Escherichia coli asparaginase with outstanding stability and enhanced anti-leukaemic activity in vitro. Scientific Reports, 2017, 7, 14479.	1.6	42
94	Asparaginase Toxicities: Identification and Management in Patients With Acute Lymphoblastic Leukemia. Clinical Journal of Oncology Nursing, 2017, 21, E248-E259.	0.3	27
95	Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy. Nanotheranostics, 2017, 1, 114-130.	2.7	10
96	COMPARATIVE CHARACTERIZATION OF L-ASPARAGINASE EXTRACTED FROM PLANT AND MICROBIAL SOURCES. International Journal of Research in Ayurveda and Pharmacy, 2017, 8, 86-89.	0.0	2
97	Acid-suppressing Drugs and a Low 1 Level of Antithrombin as Risk Factors for l-Asparaginase-associated Pancreatitis: A Case-control Study in the Japan Association of Childhood Leukemia Study (JACLS). Journal of Pediatric Hematology/Oncology, 2018, 40, 374-378.	0.3	2
98	Retrospective post-marketing study on the use of bio-similar pegasparagase among acute lymphoblastic leukemia patients in India. Pediatric Hematology Oncology Journal, 2018, 3, 9-12.	0.1	2
99	Comment on: Comparison of hypersensitivity rates to intravenous and intramuscular PEGâ€asparaginase in children with acute lymphoblastic leukemia: A metaâ€analysis and systematic review. Pediatric Blood and Cancer, 2018, 65, e27065.	0.8	4
100	Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. Journal of Oncology Pharmacy Practice, 2018, 24, 299-308.	0.5	38
101	Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2018, 59, 1797-1806.	0.6	65
102	Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2018, 65, e26873.	0.8	48
103	Expression and characterization of recombinant l -asparaginase from Pseudomonas fluorescens. Protein Expression and Purification, 2018, 143, 83-91.	0.6	39
104	Personalized nanomedicine: a rapid, sensitive, and selective UV–vis spectrophotometry method for the quantification of nanostructured PEG-asparaginase activity in children’s plasma. International Journal of Nanomedicine, 2018, Volume 13, 6337-6344.	3.3	7
105	PEG-L-CHOP treatment is safe and effective in adult extranodal NK/T-cell lymphoma with a low rate of clinical hypersensitivity. BMC Cancer, 2018, 18, 910.	1.1	9
106	Cancer Metabolism: Current Understanding and Therapies. Chemical Reviews, 2018, 118, 6893-6923.	23.0	161
107	Optimization of a Precolumn OPA Derivatization HPLC Assay for Monitoring of l-Asparagine Depletion in Serum during l-Asparaginase Therapy. Journal of Chromatographic Science, 2018, 56, 794-801.	0.7	13
108	Pharmacodynamic monitoring using biomarkers to individualize pharmacotherapy. Biomarkers in Medicine, 2019, 13, 393-408.	0.6	2
109	Amino acid metabolism in hematologic malignancies and the era of targeted therapy. Blood, 2019, 134, 1014-1023.	0.6	124

#	Article	IF	Citations
110	Long-term outcomes of modified BFM-95 regimen in adults with newly diagnosed standard-risk acute lymphoblastic leukemia: a retrospective single-center study. International Journal of Hematology, 2019, 110, 458-465.	0.7	2
111	<scp>SLC</scp> 1A3 contributes to Lâ€asparaginase resistance in solid tumors. EMBO Journal, 2019, 38, e102147.	3.5	41
112	Plasma asparaginase activity and asparagine depletion in acute lymphoblastic leukemia patients treated with pegaspargase on Childrenâ€™s Oncology Group AALL07P4. Leukemia and Lymphoma, 2019, 60, 1740-1748.	0.6	25
113	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. Haematologica, 2019, 104, 1812-1821.	1.7	32
114	Glutaminase Activity of <scp>L</scp>-Asparaginase Contributes to Durable Preclinical Activity against Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics, 2019, 18, 1587-1592.	1.9	46
115	Universal premedication and therapeutic drug monitoring for asparaginaseâ€based therapy prevents infusionâ€associated acute adverse events and drug substitutions. Pediatric Blood and Cancer, 2019, 66, e27797.	0.8	47
116	Expression, purification, and characterization of asparaginase II from Saccharomyces cerevisiae in Escherichia coli. Protein Expression and Purification, 2019, 159, 21-26.	0.6	11
117	A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora. Biologicals, 2019, 59, 47-55.	0.5	19
118	The cost-effectiveness of pegaspargase versus native asparaginase for first-line treatment of acute lymphoblastic leukaemia: a UK-based cost-utility analysis. Health Economics Review, 2019, 9, 40.	0.8	7
119	Discovery and development of small molecule modulators targeting glutamine metabolism. European Journal of Medicinal Chemistry, 2019, 163, 215-242.	2.6	31
120	Glutamine Addiction and Therapeutic Strategies in Lung Cancer. International Journal of Molecular Sciences, 2019, 20, 252.	1.8	82
121	Optimizing pegylated asparaginase use: An institutional guideline for dosing, monitoring, and management. Journal of Oncology Pharmacy Practice, 2020, 26, 74-92.	0.5	17
122	In silico analysis of codon usage and rare codon clusters in the halophilic bacteria L-asparaginase. Biologia (Poland), 2020, 75, 151-160.	0.8	5
123	Asparaginase activities during intensified treatment with pegylatedE. coliasparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 138-145.	0.6	16
124	Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 614-622.	0.6	29
125	Asparaginase: an old drug with new questions. Hematology, Transfusion and Cell Therapy, 2020, 42, 275-282.	0.1	24
126	Transformation of the L-Asparaginase II Gene to Potato Hairy Roots for Production of Recombinant Protein. Journal of Crop Science and Biotechnology, 2020, 23, 81-88.	0.7	8
127	Incidence and predictors of treatmentâ€related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28063.	0.8	9

#	Article	IF	Citations
128	FDA Approval Summary: Calaspargase Pegol-mknl For Treatment of Acute Lymphoblastic Leukemia in Children and Young Adults. Clinical Cancer Research, 2020, 26, 328-331.	3.2	30
129	National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia?. BMC Cancer, 2020, 20, 956.	1.1	1
130	Randomized, Parallel Group, Open-Label Bioequivalence Trial of Intramuscular Pegaspargase in Patients With Relapsed Acute Lymphoblastic Leukemia. JCO Global Oncology, 2020, 6, 1009-1016.	0.8	4
131	Glycosylation of Erwinase results in active protein less recognized by antibodies. Biochemical Engineering Journal, 2020, 163, 107750.	1.8	12
132	Targeting Metabolism in Cancer Cells and the Tumour Microenvironment for Cancer Therapy. Molecules, 2020, 25, 4831.	1.7	69
133	Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients. Technology in Cancer Research and Treatment, 2020, 19, 153303382098011.	0.8	2
134	Development and Validation of a Hydrophilic Interaction Liquid Chromatography Tandem Mass Spectrometry Method for the Determination of Asparagine in Human Serum. International Journal of Analytical Chemistry, 2020, 2020, 1-9.	0.4	0
135	Immunogenicity assessment of fungal l-asparaginases: an in silico approach. SN Applied Sciences, 2020, 2, 1.	1.5	5
136	Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review. Seminars in Cancer Biology, 2022, 80, 276-305.	4.3	53
137	Prospective, realâ€time monitoring of pegylated Escherichia coli and Erwinia asparaginase therapy in childhood acute lymphoblastic leukaemia and nonâ€Hodgkin lymphoma in Belgium. British Journal of Haematology, 2020, 190, 105-114.	1.2	12
138	Immunogenicity of Polyethylene Glycol Based Nanomedicines: Mechanisms, Clinical Implications and Systematic Approach. Advanced Therapeutics, 2020, 3, 1900170.	1.6	42
139	A comprehensive review on microbial <scp>l</scp>â€asparaginase: Bioprocessing, characterization, and industrial applications. Biotechnology and Applied Biochemistry, 2020, 67, 619-647.	1.4	68
140	Critical overview of the main features and techniques used for the evaluation of the clinical applicability of L-asparaginase as a biopharmaceutical to treat blood cancer. Blood Reviews, 2020, 43, 100651.	2.8	32
142	Diseases & Disorders | Therapies Targeting Glutamine Addiction in Cancer. , 2021, , 452-461.		3
143	Clinical Utility of Pegaspargase in Children, Adolescents and Young Adult Patients with Acute Lymphoblastic Leukemia: A Review. Blood and Lymphatic Cancer: Targets and Therapy, 2021, Volume 11, 25-40.	1.2	25
144	PEG-asparaginase treatment for acute lymphoblastic leukaemia in children: a network meta-analysis. The Cochrane Library, 2021, 2021, .	1.5	0
145	Circumventing the side effects of L-asparaginase. Biomedicine and Pharmacotherapy, 2021, 139, 111616.	2.5	41
146	Use of Exogenous Enzymes in Human Therapy: Approved Drugs and Potential Applications. Current Medicinal Chemistry, 2022, 29, 411-452.	1.2	16

#	Article	IF	Citations
147	L-Asparaginase-Based Biosensors. Encyclopedia, 2021, 1, 848-858.	2.4	7
148	Lâ€asparaginase doses number as a prognostic factor in childhood acute lymphoblastic leukemia: A survival analysis study. Cancer Reports, 2021, , e1533.	0.6	1
149	Role of glutamine and its metabolite ammonia in crosstalk of cancer-associated fibroblasts and cancer cells. Cancer Cell International, 2021, 21, 479.	1.8	27
150	Revealing Escherichia coli type II l-asparaginase active site flexible loop in its open, ligand-free conformation. Scientific Reports, 2021, 11, 18885.	1.6	3
151	Asparaginase: Understanding and Overcoming Toxicities. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, S90-S94.	0.2	0
152	Molecular dynamics simulations of human L-asparaginase1: Insights into structural determinants of enzymatic activity. Journal of Molecular Graphics and Modelling, 2021, 109, 108007.	1.3	1
153	Enzymes in Metabolic Anticancer Therapy. Advances in Experimental Medicine and Biology, 2019, 1148, 173-199.	0.8	19
154	Pharmacokinetic Modeling of an Induction Regimen for In Vivo Combined Testing of Novel Drugs against Pediatric Acute Lymphoblastic Leukemia Xenografts. PLoS ONE, 2012, 7, e33894.	1.1	49
155	Recombinant L-Asparaginase from Zymomonas mobilis: A Potential New Antileukemic Agent Produced in Escherichia coli. PLoS ONE, 2016, 11, e0156692.	1.1	30
156	Stromal cell-mediated mitochondrial redox adaptation regulates drug resistance in childhood acute lymphoblastic leukemia. Oncotarget, 2015, 6, 43048-43064.	0.8	35
157	Amino Acid Degrading Enzymes and their Application in Cancer Therapy. Current Medicinal Chemistry, 2019, 26, 446-464.	1.2	29
158	Insights into the Microbial L-Asparaginases: from Production to Practical Applications. Current Protein and Peptide Science, 2019, 20, 452-464.	0.7	21
159	Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 223-232.	0.9	23
160	Efficacy of Asparaginase Erwinia chrysanthemi With and Without Temozolomide Against Glioma Cells and Intracranial Mouse Medulloblastoma. Anticancer Research, 2018, 38, 2627-2634.	0.5	5
161	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated <i>E. coli</i> asparaginase in children with acute lymphocytic leukemia. Haematologica, 2022, 107, 49-57.	1.7	26
162	Cloning, Purification, Characterization and Immobilization of L-asparaginase II from E. coli W3110. Asian Journal of Biochemistry, 2008, 3, 337-350.	0.5	23
163	L-asparaginase in the treatment of patients with acute lymphoblastic leukemia. Journal of Pharmacology and Pharmacotherapeutics, 2016, 7, 62-71.	0.2	194
164	Comparison between Two Erwinia carotovora L-Asparaginase II Constructions: cloning, Heterologous Expression, Purification, and Kinetic Characterization. Journal of Microbial & Biochemical Technology, 2010, 02, 013-019.	0.2	10

#	Article	IF	Citations
165	Purification and Biochemical Characterization of Native and Pegylated Form of L-Asparaginase from <i>Aspergillus terreus</i> and Evaluation of Its Antiproliferative Activity. Advances in Microbiology, 2012, 02, 138-145.	0.3	31
166	The effect of dietary asparagine supplementation on energy metabolism in liver of weaning pigs when challenged with lipopolysaccharide. Asian-Australasian Journal of Animal Sciences, 2018, 31, 548-555.	2.4	13
167	Recent New Drug Approvals. Part 1: Drugs with Pediatric Indications. Journal of Pediatric Pharmacology and Therapeutics, 2012, 17, 329-339.	0.3	3
168	Structure, Substrate Complexation and Reaction Mechanism of Bacterial Asparaginases. Current Chemical Biology, 2007, 1, 75-86.	0.2	24
169	Nutriments et cancerÂ: alliÃ©s ou ennemisÂ?. Cahiers De Nutrition Et De Dietetique, 2020, 55, 276-294.	0.2	0
171	Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia. International Journal of Nanomedicine, 2006, 1, 241-54.	3.3	86
172	First-line treatment of acute lymphoblastic leukemia with pegasparaginase. Biologics: Targets and Therapy, 2009, 3, 359-68.	3.0	20
173	Hypersensitivity reactions associated with L-asparaginase administration in 142 dogs and 68 cats with lymphoid malignancies: 2007-2012. Canadian Veterinary Journal, 2016, 57, 176-82.	0.0	6
175	Optimizing use of L-asparaginaseâ€“based treatment of adults with acute lymphoblastic leukemia. Blood Reviews, 2022, 53, 100908.	2.8	5
176	A Targeted Catalytic Nanobody (T-CAN) with Asparaginolytic Activity. Cancers, 2021, 13, 5637.	1.7	4
177	Delivery strategies in treatments of leukemia. Chemical Society Reviews, 2022, 51, 2121-2144.	18.7	17
178	Novel Insights on the Use of L-Asparaginase as an Efficient and Safe Anti-Cancer Therapy. Cancers, 2022, 14, 902.	1.7	39
179	Role of Maintenance Treatment in Childhood Acute Myeloid Leukemia. , 0, , 250-278.		0
180	Antagonizing Glutamine Bioavailability Promotes Radiation Sensitivity in Prostate Cancer. Cancers, 2022, 14, 2491.	1.7	5
181	Pegylated asparaginase in feline high-grade lymphoma: clinical results of single injection and continued incorporation into a modified COP regimen. Journal of Feline Medicine and Surgery, 2022, 24, e203-e213.	0.6	4
182	Evaluation of PEG-L-asparaginase in asparagine suppression and anti-drug antibody development in healthy Beagle dogs: A multi-phase preclinical study. Veterinary Journal, 2022, 286, 105854.	0.6	3
183	<i>In vivo</i> stabilization of a less toxic asparaginase variant leads to a durable antitumor response in acute leukemia. Haematologica, 2023, 108, 409-419.	1.7	4
184	SOHO State of the Art Updates and Next Questions | Asparaginaseâ€"Understanding and Overcoming Toxicities in Adults with ALL. Clinical Lymphoma, Myeloma and Leukemia, 2022, 22, 787-794.	0.2	5

#	Article	IF	Citations
185	Biomaterials in Their Role in Creating New Approaches for the Delivery of Drugs, Proteins, Nucleic Acids, and Mammalian Cells in Safety Pharmacology. , 2022, , 1-27.		0
186	Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece. Clinical Drug Investigation, 2022, 42, 999-1008.	1.1	0
187	A prospective, open-label, randomised, parallel design study of 4 generic formulations of intramuscular L-asparaginase in childhood precursor B-cell acute lymphoblastic leukaemia (ALL). Cancer Chemotherapy and Pharmacology, 0, , .	1.1	0
188	Thermostability Improvement of L-Asparaginase from Acinetobacter soli via Consensus-Designed Cysteine Residue Substitution. Molecules, 2022, 27, 6670.	1.7	5
189	Identification of an Amino Acid Metabolism-Related Gene Signature for Predicting Prognosis in Lung Adenocarcinoma. Genes, 2022, 13, 2295.	1.0	1
190	Modified Asparaginase for Treatment of Cancer Historical Appraisal and Future Perspectives. Current Applied Polymer Science, 2023, 6, 14-25.	0.2	0
191	A comparison of hypersensitivity reactions between intravenous and intramuscular applications of native E. coli asparaginase in children with acute lymphoblastic leukemia. Journal of Oncology Pharmacy Practice, 0, , 107815522311645.	0.5	0
192	L-asparaginase anti-tumor activity in pancreatic cancer is dependent on its glutaminase activity and resistance is mediated by glutamine synthetase. Experimental Cell Research, 2023, 426, 113568.	1.2	2